Raymond James raised the firm’s price target on Dianthus (DNTH) to $125 from $123 and keeps a Strong Buy rating on the shares. Dianthus’ Q1 update highlighted pipeline progress including prioritized indications for DNTH212 supported by its dual BDCA2 and BAFF/APRIL mechanism, orphan drug designation for claseprubart in gMG, and multiple near-term catalysts including Phase 1 data in 2H26, a Phase 2 readout in MMN in Q4, and planned Phase 3 initiation in mid-2026 with topline results expected in 2H28, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus reports Q1 EPS (85c), consensus ($1.10)
- Dianthus treatment of myasthenia gravis gets orphan status
- Dianthus Therapeutics: Best-in-Class C1s Antibody Claseprubart and Strong Execution Support Outperform Rating
- Bullish View on Dianthus: Claseprubart’s Differentiated Complement Inhibition and Underappreciated Bifunctional Pipeline Drive Buy Rating
- Dianthus initiated with an Outperform at Wolfe Research